Fatty Acid Modulation of Bone Health

Bone is a dynamic organ continually shaped by the balanced actions of osteoblasts, which synthesise new matrix, and osteoclasts, which resorb existing tissue. Beyond their roles in energy storage and membrane structure, dietary and endogenous fatty acids modulate this balance through direct effects on bone cells and indirect influences on systemic metabolism. Saturated, monounsaturated and polyunsaturated fatty acids engage distinct signalling pathways, acting via cell-surface receptors, nuclear transcription factors and lipid-derived mediators. Long-chain omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid and docosahexaenoic acid enhance osteoblast differentiation, suppress osteoclast formation and reduce marrow adiposity. Conversely, imbalances favouring omega-6 PUFAs or certain saturated species may promote inflammation and bone loss. Receptors such as GPR120 (also known as free fatty acid receptor 4) interpret fatty acid ligands and bias bone marrow mesenchymal stem cell fate towards osteogenesis or adipogenesis in a dose-dependent manner. At the organ level, lipid metabolism intersects with endocrine regulators—adipokines, cytokines and bone-derived hormones—forming a complex network that links nutritional status, obesity, osteoporosis and healthy ageing. Understanding the mechanisms by which individual fatty acids influence bone remodelling has global significance for nutritional guidelines, therapeutic strategies and the prevention of metabolic bone diseases.

Research from Nature Portfolio

Recent studies have shown that supplementation with omega-3 PUFAs in models of diet-induced obesity restores bone mechanical strength, diminishes bone marrow adipose tissue and shifts marrow stromal cells towards osteoblastic lineage at the expense of adipogenesis. These effects coincide with reduced markers of cellular senescence and lower osteoclast formation, suggesting a more favourable microenvironment for bone formation. Foundational work on the GPR120 receptor has demonstrated that high-affinity agonists drive mesenchymal stem cells towards osteoblast commitment via ERK1/2 signalling, while lower agonist concentrations favour adipogenic pathways through p38 activation. In vivo administration of such agonists in oestrogen-deficient models rescues bone mass, highlighting the therapeutic potential of modulating fatty acid-sensitive receptors to attenuate bone loss.

Fatty Acid Modulation of Bone Health publication trend

The graph below shows the total number of articles in fatty acid modulation of bone health across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoblast: bone-forming cell responsible for extracellular matrix deposition and mineralisation.

Osteoclast: multinucleated cell that degrades bone matrix during remodelling.

Polyunsaturated fatty acids (PUFAs): fatty acids with two or more double bonds, including omega-3 and omega-6 classes.

GPR120 (FFAR4): G protein-coupled receptor sensing long-chain unsaturated fatty acids and modulating cell differentiation.

Bone marrow adipose tissue (BMAT): lipid-laden adipocytes within marrow that influence bone cell function and systemic metabolism.

RANKL: cytokine ligand activating osteoclast differentiation via receptor activator of NF-κB on precursor cells.

References

1. Crosstalk between Lipid Metabolism and Bone Homeostasis: Exploring Intricate Signaling Relationships. Research (2024).
2. Therapeutic potentials and modulatory mechanisms of fatty acids in bone. Cell Proliferation (2019).
3. Recent Advance in Regulatory Effect of GRP120 on Bone Metabolism. Aging and Disease (2023).
4. Omega-3 PUFAs prevent bone impairment and bone marrow adiposity in mouse model of obesity. Communications Biology (2023).
5. Unraveling the Omega-3 Puzzle: Navigating Challenges and Innovations for Bone Health and Healthy Aging. Marine Drugs (2024).